John J. Kirby - 25 Nov 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Reporting relationship: Interim CFO
Issuer ticker: VRCA
Reported as of: 25 Nov 2025
Net transaction value: +$15,001
SEC form: 4
Accepted by SEC: 25 Nov 2025, 19:00:14 UTC
Prior SEC filing: 06 Nov 2024
Next SEC filing: 30 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ John J. Kirby

Key filing fact

John J. Kirby filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 25 Nov 2025.

Key facts

This page summarizes John J. Kirby's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Nov 2025, 19:00.

Change

Previous filing in this sequence was filed on 06 Nov 2024.
Current net transaction value: +$15,001.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001556327 Primary reporting owner

Kirby John J.

Relationship: Interim CFO
Address: C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER
Signature: /s/ John J. Kirby
Signature date: 25 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRCA transaction

Common Stock

Purchase

Transaction value: $15,001
Shares: +3,536
Change %: +65%
Price: $4.24
Shares after: 8,962
Date: 25 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRCA transaction Derivative

Series C Warrant (right to buy)

Purchase

Transaction value
Shares: +884
Change %
Price
Shares after: 884
Date: 25 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 884
Exercise price: $6.32
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

Footnote F2

Immediately exercisable.

Footnote F3

The reported securities are included within 3,536 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.